Physician profile
Kenneth Silver
NPI 1871661686
$13,766.83
in general payments reported to CMS, 2019-2025
6 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 82% of Neurodevelopmental Disabilities (Pediatrics) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.34 · 2021: $121 · 2022: $98.10 · 2024: $12K · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,470 · Honoraria: $3,900 · Food and Beverage: $1,265 · Travel and Lodging: $821 · Education: $13.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,470.00 |
| Honoraria | $3,900.00 |
| Food and Beverage | $1,264.56 |
| Travel and Lodging | $821.04 |
| Education | $13.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $8,798.80 | 2022-2025 | Elevidys |
| Catalyst Pharmaceuticals, INC. | $4,381.48 | 2024-2025 | |
| Biogen, INC. | $363.81 | 2024-2025 | Spinraza, Skyclarys |
| Ptc Therapeutics, INC. | $144.40 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $78.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.